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Patients with alcohol-use disorders (AUDs) have a high prevalence of anxiety disorders 
(AnxDs). “Co-occurring disorders” refers to the coexistence of an AUD and/or drug 
related disorders with another non-addictive psychiatric disorder. The aim of this study 
was to assess the effectiveness of psychopharmacological treatments and psychother-
apy in patients with AUD and AnxD and to propose recommendations for the treatment 
of patients with comorbid AnxDs and AUDs. Randomized clinical trials, meta-analyses, 
and clinical guidelines were retrieved from PubMed, Embase, and Cochrane databases. 
Paroxetine was found to be effective in social anxiety patients with alcohol dependence. 
Selective serotonin reuptake inhibitors (SSRIs), especially sertraline, showed effective 
results in posttraumatic stress disorder and in comorbid AnxD–AUD. However, SSRIs 
should be used with caution when patients are actively drinking because they may 
increase alcohol consumption. Buspirone, gabapentin, and pregabalin were found to 
be effective in comorbid AnxD–AUD. The treatment of dual AnxDs should start as early 
as possible. Since AUDs and AnxDs can reinforce each other, treatments targeting both 
pathologies can be effective. Women suffer from higher levels of stress and AnxDs than 
men, and they are also more vulnerable to maintaining alcohol consumption levels. 
Further research is needed in this comorbid patient population, including the study of 
different types of patients and gender perspectives.
Keywords: alcohol-use disorder, anxiety disorders, comorbidity, co-occurring disorders, treatment recommendations
Abbreviations: AnxD, anxiety disorder; AUD, alcohol-use disorder; AWS, alcohol withdrawal syndrome; BAP, British 
Association of Psychopharmacology; BZD, benzodiazepines; CBT, Cognitive–Behavioral Therapy; CME, Continuing Medical 
Education; DSM, Diagnostic and Statistical Manual of Mental Disorders; DT, distress tolerance; EMCDDA, European 
Monitoring Center for Drugs and Drug Addiction; GABA, Gamma-aminobutyric acid; GAD, generalized anxiety disorder; 
GPR, Good Practice Recommendations; NaSSA, Noradrenergic and Specific Serotonergic Antidepressants; NMDA, N-methyl-
d-aspartate receptor; NIDA, National Institute on Drug Abuse; OCD, Obsessive–Compulsive Disorder; OR, odds ratio; PTSD, 
posttraumatic stress disorder; RCT, randomized clinical trials; SEPD, spanish society on dual disorders; SNRIs, serotonin 
noradrenalin reuptake inhibitors; SSRI, selective serotonin reuptake inhibitor antidepressants; SMH, self-medication hypoth-
esis; SUD, substance-use disorder; TRH, tension reduction hypothesis.
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iNTRODUCTiON
Anxiety disorders (AnxDs) are often combined with alcohol-use 
disorders (AUDs), worsening the symptoms, and making treat-
ment more difficult. Comorbid AnxDs and AUDs are associated 
with poorer treatment results and increased difficulties in treat-
ment with standard psychosocial interventions (1). Problematic 
alcohol consumption is defined as a pattern that causes mental 
and physical health damage and serious alterations in the subject’s 
life and in the lives of those in his or her social environment and 
represents a major political concern (2, 3).
Anxiety disorders are characterized by the presence of fear, 
excessive anxiety, and behavioral changes. Fear is an emotional 
response to an immediate threat, real or imagined, while anxiety 
is an anticipatory response to a future threat, real or imagined. 
Fear is typically associated with the autonomic activation needed 
for defense and flight, and fearful thoughts (imminent danger) 
are associated with flight conduct. Anxiety is associated with 
muscular tension, awareness of future danger, and cautious and 
avoidant behavior (2). Posttraumatic stress disorder (PTSD) 
has also been included, following the American Psychiatric 
Association Diagnostic Classification Diagnostic and Statistical 
Manual of Mental Disorders (DSM)-IV-TR (4).
In general, the terms “dual disorders” or “co-occurring disor-
ders” are used when referring to the broad clinical patient popula-
tion suffering from substance use and other psychiatric disorders.
According to the National Institute on Drug Abuse (NIDA), 
the term “comorbidity” describes two or more disorders or ill-
nesses occurring in the same person. These disorders can occur 
simultaneously or consecutively. Comorbidity also implies 
interactions between the illnesses that can worsen the course of 
both (5).
The European Monitoring Center for Drugs and Drug 
Addiction defines “comorbidity/dual diagnosis” as the “temporal 
coexistence of two or more psychiatric disorders as defined by the 
International Classification of Diseases” (6).
The comorbidity of alcohol dependence with another psychi-
atric disorder is very common (7–10), while the association of 
AUDs with other neuropsychiatric illnesses, such as depression 
or AnxDs, is also very frequent (11–14).
The diagnosis is challenging due to the possibility of multiple 
causes. Symptoms of anxiety may be caused by abstinence or 
intoxication effects (induced AnxDs). It is also possible that one 
disorder may be, directly or indirectly, induced by the other. 
For example, a subject may turn to substance consumption as a 
means to cope with anxiety; AnxDs may be triggered by the stress 
associated with substance consumption (15). The observation of 
anxiety symptoms in patients who have been abstinent for several 
weeks allows us to determine whether the patient is presenting 
with abstinence- or intoxication-induced anxiety or whether they 
should be diagnosed with primary AnxD (16).
There are various theoretical models defining the relationship 
between AUDs and AnxDs. The models that give priority to AnxDs 
generally accept the idea that it is the effort of coping with situations 
that provokes anxiety, which in turn leads to alcohol abuse. These 
models include the tension reduction hypothesis (17) and the self-
medication hypothesis (18), and they can be particularly relevant 
in cases of AnxD that normally precede the emergence of depend-
ency, such as general AnxD and agoraphobia (17–19). In fact, the 
evidence of a causal relationship between AnxD symptoms and the 
symptoms of AUDs includes a possible dose–response relationship 
between the severity of the symptoms of social phobia and the level 
of alcohol consumption (20), as well as the finding that early treat-
ment of AnxDs reduces alcohol abuse (1, 21, 22).
Alcohol is a psychotropic depressant of the central nervous 
system that promotes simultaneous changes in several neuronal 
pathways, exerting a profound neurological impact that leads to 
various behavioral and biological alterations (23).
The direct effect of alcohol on several neurotransmitter 
receptors [gamma-aminobutyric acid [GABA], glutamate, 
endocannabinoids AEA and 2-AG, among others] has been 
described (23). More specifically, alcohol enhances the GABA 
action and antagonizes glutamate action (24). On the other 
hand, GABAergic and glutamatergic systems seem to be 
involved in AnxD, such as Generalized anxiety disorder (GAD), 
panic disorder, and social AnxD (25). Furthermore, glutamate 
signaling mediates certain aspects of the intoxicating and 
rewarding effects of alcohol and chronic alcohol abuse produces 
a hyperglutamatergic state (26).
One of the five major components of the glutamate system, 
the N-methyl-d-aspartate (NMDA) receptor (27), could play a 
role in the risk of benzodiazepine abuse. In this sense, the NMDA 
receptor antagonist-benzodiazepine has been involved in abuse 
liability (28). Thus, this medication should be used very carefully 
when treating AUD patients.
However, different classifications of alcohol users could be 
considered. Cloninger et al. (28) defined two types of alcoholism, 
based on alcohol-related symptoms, personality traits, age of 
onset, and patterns of inheritance. Type 1 alcoholism was defined 
by anxious personality traits and the rapid development of toler-
ance and dependence on the antianxiety effects of alcohol. Babor 
et al. (29) also focused on two types: Type A was characterized by 
a later onset, fewer childhood risk factors, less severe dependence, 
fewer alcohol-related problems, and less psychopathological 
dysfunction. This typology, which is similar to Cloninger’s types, 
could help explain the different causes, courses, prognoses, and 
outcomes for the disorder (30).
It is estimated that more than 51% of people with psychi-
atric disorders abuse or depend on psychoactive substances 
(11, 14), especially alcohol. The presence of a psychiatric disorder 
increases the risk of progressing from mere consumption to alco-
hol dependency (31). In fact, 37% of AUD patients suffer from 
other psychiatric disorders. Alcohol dependence is associated 
with an increased risk of mood disorders (three times higher), 
AnxDs in general (twice as high), generalized AnxD (four times 
higher), panic disorders (almost double), and posttraumatic 
stress disorder (twice as high) (32–34).
Anxiety disorders and other psychiatric disorders in patients 
with substance-use disorders (SUDs) have a significant impact 
on treatment results (35, 36). Anxiety, considered as a symptom, 
decreases in abstaining patients, yet if it remains present, the risk 
of a relapse is two times higher (37–40).
“Off-label prescription” indicates that the medication is 
being used in a manner not specified in the approved Summary 
TAble 1 | Scientific institutions and associations web pages consulted for 
clinical guidelines on treatment of comorbid AnxD–alcohol-use disorders patients.
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of Product Characteristics (therapeutic indications in other 
conditions, unapproved changes in dosage and/or duration 
of treatment) (41). However, such situations, which should be 
exceptional, are frequent in clinical practice, especially in a field 
such as psychiatry, and they occur frequently in patients with 
comorbidity (42) whose situations require drug combinations 
(43). The Agency for Healthcare Research and Quality (44) 
stated that the most common uses of psychiatric drugs unap-
proved on the labeling appear in the treatment of depression, 
obsessive–compulsive disorder (OCD), PTSD, personality 
disorders, Tourette syndrome, autism, and agitation in demen-
tia (44).
Currently, there are many drugs approved for the isolated 
treatment of AnxDs or AUDs. However, there is little certainty 
in cases of patients with comorbid AnxDs and AUDs, and it is 
not clear whether the recommendations issued separately for 
patients with AnxDs or AUDs can be accepted in comorbid 
patients. Furthermore, several studies have been carried out using 
non-approved medicines (off-label prescription) in patients with 
AUD and AnxD.
The aim of this study was to assess the effectiveness of psy-
chopharmacological treatments and psychotherapy in patients 
with AUD and AnxD, and to propose recommendations for the 
treatment of patients with comorbid AnxDs and AUDs. The 
influence of age and gender were also analyzed.
MATeRiAlS AND MeTHODS
literature Search
The authors undertook an extensive review of publications, 
meta-analyses and Randomized Clinical Trials (RCTs), address-
ing AnxD and AUD treatments. Database searching through July 
2016, was carried out using MEDLINE/PubMed, Embase, and 
Cochrane Database of Systematic Reviews platforms.
In a first stage, a search was performed using the terms: 
(i) “anxiety disorders” and “anxiety symptoms”; (ii) “alcohol addict,” 
“alcohol abuse” and “alcohol,” (iii) “naltrexone,” “disulfiram,” “atypi-
cal antipsychotics,” “antidepressants,” “SSIRs,” “mood stabilizer,” 
“anticonvulsants,” “buspirone,” and “benzodiazepine.”
In a second stage, a search combining the results obtained in 
the previous searches was performed, aiming at identified articles 
that contained at least one term from each of the three identified 
groups (anxiety, alcohol, and psychotropic drugs).
A total of 121 works were identified, of which 50 were RCTs. 
After a thorough manual selection process, the total was reduced 
to 21, having discarded publications that did not fulfill the RCT 
criteria or did not cover AnxD and AUD. No meta-analysis was 
found on the topic.
Clinical Guidelines Analysis
The main clinical guidelines were reviewed in a parallel analysis 
to contrast the evidence and degrees of scientific recommenda-
tions. The search strategy was applied based on the following 
terms.
•	 In MEDLINE/PubMed: using the following key words 
“guidelines of alcohol abuse,” “harmful use,” “addiction and 
comorbidity addiction,” and “dual diagnosis.”
•	 In the RIMA Network (https://www.rima.org): searching for 
guidelines through the psychiatric portal.
Guidelines of the British Association of Psychopharmacology 
(BAP) were obtained (45).
Moreover, scientific associations’ Web pages were consulted 
for works on scientific evidence in this field of knowledge, and 
the names and “URLs” are mentioned in Table 1.
level of evidence
We used the recommendations suggested by the Center of 
Evidence-Based Medicine of Oxford (46), to establish levels 
of evidence and make recommendations based on the RCT 
identified.
ReSUlTS
Below is a description of the most relevant findings, based on the 
content analysis of comorbid AUD–AnxD treatment (Table 2).
Treatment Results—General Observations
The bibliographic analysis showed a heterogeneous picture of the 
combined effects of AnxDs and AUDs. There is no certainty of 
the impact that AnxD has on the results of alcohol consumption; 
although some studies suggested similar treatment results in 
persons with or without comorbid AnxD, a poorer prognosis was 
suggested by others (15).
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A recent clinical trial (47) performed in primary care with 
1,004 patients and an 18-month follow-up period analyzed the 
relationship between AnxDs and AUDs. It examined the impact 
of alcohol-use symptom severity (patients with alcohol abuse were 
included, but patients with alcohol dependence were excluded) 
on AnxD treatment outcomes. The majority of analyses revealed 
no predictive effects of alcohol-use severity on outcome; however, 
baseline alcohol problems were associated with somewhat higher 
anxiety and depression symptoms at the 18-month follow-up. It 
was concluded that there might be no need to postpone treatment 
of AnxDs until alcohol problems were addressed. Moreover, it was 
indicated that alcohol consumption should not modify a thera-
peutic approach in AnxD patients. It was concluded that delaying 
treatment for anxiety until the alcohol consumption problems had 
been resolved was not necessary, especially concerning patients 
who had not reached dependency criteria. Taking into account 
the hypothesis of consumption as self-medication, in which the 
patient takes to alcohol in order to calm his/her symptoms, it can 
be deduced that treating the anxiety will help to limit the alcohol 
consumption and its persistence, as well as avoiding any worsen-
ing of the consumption. The combined treatment models would 
include cognitive and pharmacological therapy, either singly or 
combined (47). Level of evidence: 1b.
Gender Considerations
Several studies have attempted to evaluate possible gender differ-
ences in the frequency of comorbid AnxDs and AUDs. Population 
surveys have consistently shown that AnxDs are more common 
among women, whereas AUDs are more common among men 
(48).
Women have an increased likelihood of independent AnxDs 
compared with men, but prior AnxDs were also more strongly 
predictive of later alcohol dependence among women.
Regarding typology, gender showed some differences. For 
example, Cloninger’s type II was essentially limited to men, while 
in the Babor et al. study (29), men were equally classified as type 
A or type B, but women were slightly more frequently classified as 
type A. Therefore, men were more frequently assigned to types II 
or B (29).
A multicentre trial found that AnxDs had a substantial influ-
ence on the course and severity of alcoholism in women (49). The 
women with AnxDs had faster dependence evolution, including 
earlier first drink onset and shifting to regular consumption and 
a greater incidence of abstinence symptoms. One potential expla-
nation is that the reasons for using alcohol can differ by gender. For 
example, women might be more prone than men to self-medicate 
with alcohol for mood problems (50–52). Furthermore, empiri-
cal inspection of gender differences in stress-related drinking 
has shown that women report higher levels of stress and have a 
stronger link between stress and drinking (53, 54).
In turn, evidence has revealed in studies performed over the 
last 25  years a high comorbidity of PTSD and AUDs (55, 56). 
Another study concluded that there was a two times greater pro-
pensity to develop alcohol dependency [odds ratio (OR) = 1.85] 
in women exposed to trauma, while women with PTSD exposed 
to trauma were even more likely (OR = 3.54) to develop alcohol 
dependency than women with only trauma (54, 55).
Age Considerations
Multiple forms of anxiety psychopathology are associated with 
alcohol use problems in adolescents. A recent crosssectional 
study (21) provided preliminary evidence of two cross-diagnoses: 
distress tolerance (DT) and anxiety sensitivity. A crosssectional 
study that examined a sample of 534 high school students 
(14–15 years old) found that the multiple manifestations of anxi-
ety were associated with greater alcohol use problems; however, 
this association was not found in the case of DT. The authors 
suggested that anxiety sensitivity could be an important trans-
diagnostic target for alcohol prevention programs for those in 
early adolescence who experience elevated anxiety symptoms.
In addition to alcohol consumption disorders, child care negli-
gence or childhood adversities were associated with a greater risk 
of PTSD (54). Studies in samples of individuals seeking treatment 
for AUDs have also found a high prevalence of reported child-
hood adversity and PTSD. In a study in men and women treated 
for SUDs, 26% reported having been victims of childhood physi-
cal or sexual abuse (14). A review of studies of individuals seeking 
treatment for addictions revealed rates of PTSD as high as 50% or 
higher (54–57). The development of PTSD usually precedes the 
development of SUDs.
Comorbid AnxD and AUD Pharmacological 
Treatment Considerations
Atypical Antipsychotics
Some authors (58, 59) have found that quetiapine may be a 
promising agent for non-comorbid GAD, whereas more studies 
are needed before making practical recommendations on the use 
of olanzapine and risperidone. Risperidone and olanzapine add-
on could play a role in resistant or chronic posttraumatic stress 
disorder patients, although only the addition of risperidone can 
be recommended on the basis of the criterion of two or more 
positive placebo-controlled trials (60).
However, there have been few studies on the use of antipsy-
chotics in AnxD and AUD patients. A retrospective controlled 
study (61) found that the mean number of abstinence days was 
significantly greater and the number of hospitalizations was 
significantly lower for the quetiapine group during the period 
studied. Level of evidence: 4.
A review from an expert opinion on aripiprazole might pro-
vide a novel therapeutic approach for alcoholism by attenuating 
craving (during the abstinence phase) and anxiety, depression, 
and impulsivity, which are potentially responsible for relapses and 
the worsening of drinking behaviors. Subjects with a Cloninger II 
personality profile are characterized by higher levels of impulsive-
ness, sensation seeking, early onset of alcohol misuse, antisocial 
behavior and reward craving. In these conditions, aripiprazole 
has shown some level of evidence in different studies (62, 63). 
Level of evidence: 4 (Table 2).
Use of Antidepressants
There is preliminary evidence that combined psychotherapeutic/
mirtazapine treatment (30–60 mg/daily) has a greater impact on 
AnxD symptoms than non-pharmacological treatment alone. 
These authors also found a high incidence of social anxiety 
TAble 2 | Pharmacological treatments of comorbid AnxDs and AUDs patients: main scientific publications and findings.
Author/team Clinical condition Trial design/duration Sample/doses Results
Atypical antipsychotics: quetiapine
Monnelly et al. (61) PTSD Retrospective 
Controlled/12 months
N = 50/25–200 mg/night The average abstinence duration was significantly longer. 
Hospitalization was shorter in the quetiapine group; the 
difference was statistically significant
Antidepressants NaSSAs: mirtazapine
Liappas et al. (64) Social anxiety Open/4–5 weeks after 
detoxification period
N = 54/30–60 mg/daily There was high remission probability in social anxiety 
symptoms in AUD in-patients after alcohol detoxification. The 
study provided preliminary evidence that psychotherapeutic 
treatment combined with mirtazapine (30–60 mg/day) had a 
greater impact on symptoms than pharmacological treatment 
alone.
A longer follow-up period was needed to determine remission 
levels
Non-selective monoamine reuptake inhibitors antidepressants: nefazodone + psychotherapy
Hernadez-Avila et al. (67) Anxiety symptoms  
in AUD patients  
with major 
depression
RCT/10 weeks N = 41/200–600 mg/day Depression and anxiety symptoms decreased significantly 
with time. The nefazodone group showed higher symptom 
reduction; however, the difference did not attain statistical 
significance. Nefazodone patients showed significantly greater 
symptom reduction and a reduction in the total number of 
drinks on days of excessive drinking, compared with subjects 
treated with placebo. The lack of significant effects on 
depression and anxiety symptoms might reflect limitations of 
the statistics. Despite the rather small size of the sample group, 
nefazodone helped to reduce some means of consumption in 
the depressive AUD patients
Trazodone
Janiri et al. (65) Anxiety Open/12 weeks N = 25/50–100 mg/day In the detoxified AUD patient sample, trazodone showed 
anxiolytic, anti-depressive, and anti-craving efficacy. Little 
evidence, small sample, open study
Paroxetine
Randall et al. (69) Social anxiety RCT/8 weeks N = 15/20–60 mg/day Paroxetine was effective in social anxiety and AUD. Patients 
with alcohol dependence—6 with social anxiety who were 
given paroxetine and 9 who were given a placebo over 
8 weeks—were compared. The paroxetine group improved 
significantly in one of the social anxiety indicators (effect 
size = 0.81)
Thomas et al. (70) Social anxiety RCT/16 weeks N = 42/40–60 mg/day Paroxetine reduced social anxiety and alcohol consumption 
(self-medication use for social phobia)
Book et al. (71) Social anxiety RCT/16 weeks N = 42/40–60 mg/day Paroxetine reduced social anxiety
Sertraline
Brady et al. (73) PTSD RCT/12 weeks N = 94/150 mg/day Sertraline was associated with better mood and drinking 
outcomes in the subgroup with early-onset PTSD and 
later onset and less severe alcohol dependence, whereas 
among those with later-onset PTSD and more severe alcohol 
problems, sertraline was not better than the placebo. There 
could be subtypes in patients with severe or moderate AUD 
and early or later-onset PTSD that require different therapeutic 
strategies
Pettinati et al. (75) Alcohol-dependent 
subjects
RCT/14 weeks N = 100/200 mg/day A significant interaction between the alcoholic subtype and 
the medication condition was found, confirming the findings. 
Alcoholic subtypes responded differentially to serotonergic 
medications. Somewhat at variance with their results, however, 
the present study showed that the lower risk/severity (Type 
A) subjects had more favorable outcomes when treated with 
sertraline, compared to the placebo
Labbate et al. (76) PTSD RCT/12 weeks N = 93/50 mg/day Anxiety or mood disorder comorbidity did not decrease 
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Author/team Clinical condition Trial design/duration Sample/doses Results
Anxiolytics: buspirone
Kranzler et al. (77) Generalized anxiety RCT/12 weeks N = 61/Maximum dosage 
of 60 mg/day
Buspirone therapy was associated with greater retention in 
the 12-week treatment trial, reduced anxiety, a slower return 
to heavy alcohol consumption, and fewer drinking days during 
the follow-up period. GAD and AUD patients received weekly 
relapse prevention psychotherapy
Bruno (81) Anxiety RCT/8 weeks N = 50/15–30 mg/day Buspirone significantly reduced the Hamilton Anxiety Rating 
Scale total scores (p = 0.006)
Tollerfson et al. (82) Social anxiety RCT/24 weeks N = 51/60 mg/day Buspirone was superior to placebo as an anxiolytic
Gabapentin
Myrick et al. (85) Anxiety RCT/12 days N = 84/900–120 mg/day Participants treated with a high (1,200 mg) or a low (900 mg) 
dose of gabapentin had lower probabilities of drinking 
during the treatment period and during a 1-week follow-up 
posttreatment period. During the trial period, the subjects 
treated with the high dose of gabapentin had lower anxiety 
levels and a better capacity to perform tasks than the subjects 
treated with lorazepam. The gabapentin groups also had 
less craving, anxiety, and daytime sedation, compared to 
lorazepam. During treatment, low-dose gabapentin-treated 
participants had less craving and anxiety, as well as less 
depression syndromes
Pregabalin
Di Nicola et al. (87) AUD Open, 
Prospective/14 days
N = 40/200–450 mg/day Alcohol withdrawal symptoms and craving for alcohol were 
significantly reduced over time after pregabalin treatment. 
Pregabalin also resulted in a favorable improvement in 
psychiatric symptoms and quality of life







Compared with naltrexone, pregabalin resulted in a greater 
improvement in specific symptoms in the areas of anxiety, 
hostility, and psychosis and the duration of abstinence from 
alcohol. Pregabalin also resulted in a better outcome in patients 
reporting a comorbid psychiatric disorder. Results from this 
study globally placed pregabalin within the same range of 
efficacy as naltrexone







Pregabaline, lorazepam, and tiapride showed evidence of safety 
and efficacy in the treatment of uncomplicated forms of AWS. 
The efficacy of pregabalin was superior to that of tiapride, and, 
for some measures, to that of, lorazepam
Opioid antagonist: naltrexone
Petrakis et al. (92) Anxiety RCT/12 weeks N = 254/50 mg/day 
Naltrexone; 250 mg/day 
disulfiram
There was a high rate of abstinence across groups. Subjects 
treated with an active medication had significantly more 
consecutive weeks of abstinence and less craving than those 
treated with a placebo, but there were no significant group 
differences in other measurements of alcohol consumption. 
There was no advantage in the combination of both 
medications
Petrakis et al. (93) PTSD RCT/12 weeks N = 254/50 mg/day 
Naltrexone; 250 mg/day 
disulfiram
Subjects with PTSD had better alcohol outcomes with active 
medication (naltrexone, disulfiram, or the combination) than 
they did on a placebo; the overall psychiatric symptoms of 
PTSD improved. Individuals with PTSD were more likely to 
report some side effects when treated with the combination. 
Curiously, the group with only disulfiram also reported fewer 
PTSD symptoms. This finding represents a potentially confusing 
factor because it seems possible that it is abstinence that might 
be responsible for the improvement in PTSD symptoms. It is 
suggested that patients whose aim in treatment is to abstain 
from alcohol might be more prone to experiencing a reduction 
in PTSD symptoms
(Continued)
TAble 2 | Continued
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Author/team Clinical condition Trial design/duration Sample/doses Results
Psychopharmacological strategy: pharmacological treatment and psychotherapy
Schade et al. (95) Social anxiety/social 
phobia
RCT/32 weeks N = 96 Alcohol dependence and comorbid social phobia and/or 
agoraphobia patients were randomly assigned to an intensive 
psychosocial relapse prevention programme (n = 49) or, in 
combination, to an anxiety treatment programme that included 
CBT and optional pharmacotherapy using SSRIs. Although the 
combined therapy clearly reduced anxiety symptoms, it had no 
significant effects on alcohol relapse levels
Randall et al. (72) Social anxiety RCT/12 weeks and 
3 months after the end  
of treatment
N = 93 The design was a two-group, randomized clinical trial using 
12 weeks of individual (CBT) for alcoholism only (n = 44) 
or concurrent treatment for both alcohol and social anxiety 
problems (n = 49). The results showed that both groups 
improved (there was no significant difference) in alcohol-
related outcomes (percentage of abstinence days and days of 
excessive drinking); moreover, both groups improved in social 
anxiety and phobia during the treatment and follow-up periods
AnxD, anxiety disorder; AUD, alcohol-use disorder; AWS, alcohol withdrawal syndrome; CBT, cognitive behavioral therapy; GAD, generalized anxiety disorder; NaSSAs, 
noradrenergic and specific serotonergic antidepressants; PTSD, posttraumatic stress disorder; RCT, randomized clinical trials; SNRIs, serotonin noradrenalin reuptake inhibitors; 
SSRI, selective serotonin reuptake inhibitor.
TAble 2 | Continued
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symptoms subsiding in in-patient alcoholics following alcohol 
detoxification (64). Level of evidence: 4.
Trazodone is a widely used drug in clinical practice (65, 66). 
However, we found only one open study with 25 AUD patients. 
The authors reported anxiolytic, anti-depressive and anti-craving 
effects of trazodone when patients were treated with a dose of 
50–100 mg/day (65). Level of evidence: 4.
The use of antidepressants was tested in a RCT in AUD 
patients with comorbid AnxD and major depression. Subjects 
were randomly assigned to receive nefazodone and supportive 
psychotherapy. Depressive and anxiety symptoms declined 
significantly over time. Although the nefazodone group showed 
greater reductions in these symptoms, the effects did not attain 
statistical significance. Nonetheless, nefazodone-treated subjects 
showed a significantly greater reduction in heavy drinking days 
and in total drinks compared with placebo-treated subjects (67). 
Level of evidence: 1a.
Several reviews have found good results with the selective 
serotonin reuptake inhibitors (SSRIs) in comorbid AnxD and 
AUD treatment (68). Paroxetine is the antidepressant for which 
the most scientific evidence was found for dual anxiety treatment 
(68–70). Three clinical trials (69–71) found that paroxetine was 
effective in social anxiety patients with alcohol dependency. Level 
of evidence: 1a.
Other authors have emphasized the importance of combina-
tions of psychotherapeutic interventions/treatments combined 
with pharmacological SSRI treatment or topiramate when man-
aging comorbid PTSD and alcohol dependency patients (71–73).
In turn, a systematic review emphasized that drugs such as 
SSRIs, especially sertraline, were effective in PTSD and in comor-
bid AnxD-AUD (74). Two randomized clinical trials (75, 76) 
found evidence of sertraline treatment efficacy in alcoholics with 
PTSD. However, although sertraline can be effective in PTSD 
treatment (55), there is little evidence for SSRI efficacy in alcohol 
consumption. Level of evidence: 1a.
Moreover, other studies have suggested that there might be 
alcoholic subtypes that respond differentially to serotonergic 
medication (75). One detailed analysis showed that sertraline 
treatment in patients whose traumatic experience occurred prior 
to the development of alcohol dependence improved drinking 
results. However, sertraline-treated patients with grave depend-
ence and PTSD drank more than placebo-treated patients. Level 
of evidence: 1a.
A significant interaction between the alcoholic subtype and 
the response to medication was found in a randomized controlled 
trial with 100 AUD patients (75), confirming previous findings 
(77) that alcoholic subtypes responded differently to serotonergic 
medications. Pettinati’s trial showed that those with lower risk/
severity of alcoholism had more favorable drinking outcomes in 
response to treatment with sertraline than with a placebo (75). 
Level of evidence: 1a.
The Socidrogalcohol clinical guidelines recommend (78) using 
SSRIs with caution if the patient is actively drinking because the 
agents can lead to an increase in alcohol consumption in some 
patients (79). Level of evidence: 1b.
However, these guidelines also state that SSRIs are preferred 
in comorbid AnxD and AUD treatment due to their low abuse 
potential, rare interactions and low overdose risk. The recom-
mended dosage follows the insert indications. There was also a 
suggestion that panic-crisis patients with an alcohol consumption 
history or AnxD family history could be recommended for an 
early start of AnxD treatment without waiting for abstinence (78).
Use of Anxiolytics
The latest Good Practice Recommendations of the French Alcohol 
Society and the guidelines of the BAP (45, 80) suggest the use of 
benzodiazepines (BZD) only in alcohol detoxification in-patients 
(under clinical control). BZD treatment longer than 1 week is 
justified only when abstinence symptoms persist or in the case 
of an associated BDZ dependence. The French expert group 
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recommended that, in no case should BZD treatment continue for 
more than 4 weeks. In agreement, the Socidrogalcohol guidelines 
(78, 79) recommend extreme caution in the use of BZD due to the 
greater risk of the development of a tolerance and dependence in 
patients with AUDs and AnxDs (77). Level of evidence: 2a.
Benzodiazepines should be used with caution because of the 
risk of abuse and overdose when associated with alcohol or other 
central nervous system depressants, such as opioids (45). Level 
of evidence: 2a.
Buspirone was found to be effective in comorbid AUD and 
AnxD patients (81, 82), an other clinical situations (83). In 
addition, buspirone was associated with greater retention, 
anxiety reduction, slower return to excessive drinking, and a 
smaller number of days of drinking. All of the treated patients 
also received weekly relapse prevention therapy (82). Level of 
evidence: 1a.
Use of Anticonvulsants
Gabapentin is effective in AnxD and AUD treatment (84). An 
RCT with high- (1,200  mg/day) and low- (900  mg/day) dose 
gabapentin- vs. lorazepam-treated AUD patients reported an 
improvement in anxiety symptoms in the lorazepam patients. 
The high-dose gabapentin patients had less alcohol craving, less 
anxiety and less daytime sedation (85). Level of evidence: 1a.
Other anticonvulsants have shown a capacity for anxiety 
symptom improvement in AUD patients. A randomized and 
open-label trial of 182 AUD patients (86) found that topiramate, 
at a mean dose of 200 mg/day, was better than naltrexone, at a 
mean dose of 50  mg/day, at reducing alcohol intake and crav-
ing and anxiety throughout the 6-month study period. Level of 
evidence: 1b.
Moreover, the molecule with the best evidence that also 
includes indications for GAD on the labeling is pregabalin (87). 
An RCT was published comparing pregabalin and naltrexone 
(88). The alcohol drinking index and craving scores were not 
significantly different between the groups. However, compared 
with naltrexone, pregabalin resulted in greater improvement in 
specific symptoms in the areas of anxiety, hostility, and psychosis, 
and survival function (duration of abstinence from alcohol). 
Level of evidence: 1a.
The mechanism involved in the efficacy of pregabalin in 
relapse prevention could be more associated with anxiety 
control than with craving (87, 89). Additionally, the available 
literature suggests important clinical abuse potential of prega-
balin. Therefore, prescribers should pay attention to the signs 
of abuse (90, 91).
Use of Opioid Antagonists
An RCT comparing naltrexone vs. disulfiram was performed in 
AUD patients. The investigators found an improvement in anxiety 
symptoms in both naltrexone and disulfiram patients. There was 
no significant advantage of the combination of both medications 
(92). Level of evidence: 1a.
Moreover, there was a high rate of abstinence across 
groups. PTSD patients treated with an active medication 
(naltrexone, disulfiram, or in combination) had significantly 
better abstinence and craving results. There was also an overall 
improvement in the psychiatric symptoms of PTSD (93). Level 
of evidence: Ia. Curiously, the group treated with disulfiram also 
reported fewer PTSD symptoms. Here, abstinence could be the 
key factor in the improvement of the PTSD symptoms.
In contrast, Nalmefene, is an μ and δ opioid receptor 
antagonist and κ partial agonist. Nalmefene can be admin-
istered safely in alcohol dependence and can significantly 
prevent relapse to heavy drinking (94). Level of evidence: Ib. 
No studies involving this drug in comorbid AnxDs and AUDs 
have been published.
Comorbid AnxD and AUD 
Psychotherapeutic interventions 
Considerations
An RCT showed that combined therapy (medication + therapy) 
clearly reduced anxiety symptoms (95). It had no significant effect 
on alcohol relapse rates (95). Level of evidence: 1a.
A systematic review concluded that motivational interview-
ing and cognitive–behavioral interventions were associated with 
significant reductions in alcohol consumption and depressive 
and/or anxiety symptoms (96). Although brief interventions 
were associated with significant improvements in mental health 
and alcohol variables, longer interventions produced even better 
outcomes (72, 95–97). Level of evidence: 1a.
DiSCUSSiON
General Considerations
There is insufficient evidence to confirm that the presence of 
comorbid AnxDs and AUDs has a negative effect on treatment 
results with regard to the manifestation of their separate forms 
(1, 15). The available literature is challenging to interpret because 
of the substantial heterogeneity of the studies with respect to study 
design, diagnostic assessment variability, type of treatment, and 
different clinical populations; all of these factors could explain the 
lack of relevant and conclusive information (15).
Regarding gender, various randomized clinical trials have 
examined whether AnxDs, when diagnosed at the beginning of 
the trial, were associated with alcohol consumption in women. 
RCTs in female AUD patients with AnxDs showed a weak 
association, with more days of drinking during the 6-month 
follow-up. Moreover, the presence of AnxDs during the trial was 
related to actual drinking (49). An early start in the treatment of 
AnxDs may be appropriate, as well as not waiting until alcohol 
problems are addressed, at least among those who have mild-
to-moderate alcohol problems (47). Other authors recommend 
2–4 weeks of abstinence before initiating treatment, using drugs 
with low abuse potentials, so the BZD should be avoided. The use 
of medication should be reserved for persistent anxiety, evaluat-
ing the risk of intoxication and interactions with alcohol or drug 
abuse (45, 78).
It would be useful to examine the potential risks of cross-
recruitment for the different psychopharmacological categories, 
given that the psychiatric drugs may be affected by substance 
abuse and those patients can perhaps abuse the psychiatric 
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drug itself. The clinic should carry out an evaluation of the pos-
sible interactions between the pharmacological treatment and the 
substances of abuse, as well as paying attention to the possible 
implications for the patient’s mental health.
The start of the psychopharmacological treatment in patients 
with comorbid AnxD and AUD requires a detailed clinical 
evaluation of the benefits/risks profile. The pharmacological 
interactions should be taken into account when choosing the 
psychotropics. Much care should also be taken with the SSRIs, as 
some symptoms of abstinence from alcohol can become super-
imposed or even added to the serotoninergic activation. For this 
reason, it is necessary for the clinic to pay careful attention to the 
interactions and to the precise identification of the symptoms so 
as to be able to control the effects and risks resulting from the 
medication itself (98, 99). The current tendency, however, is to 
recommend the use of the necessary medication while taking due 
precautions and with a high degree of care to identify any adverse 
effect derived from the medication or its interaction with alcohol 
or drug abuse, not to forget vigilance concerning the possible 
effects on the patient’s mental health.
Posttraumatic Stress Disorder
Posttraumatic stress disorder (PTSD) and SUD frequently co-
occur, and their combination can increase poor health outcomes 
as well as mortality. The shared neurobiological features of these 
two illnesses include amygdalar hyperactivity with hippocampal, 
medial prefrontal, and anterior cingulate cortex dysfunction 
(100–102).
Regarding age, the findings contain preliminary evidence for 
the trans-diagnostic anxiety sensibility concept that encompasses 
a variety of anxiety manifestations (21). This condition is associ-
ated with greater posterior alcohol consumption problems. The 
relationship between the presence of a trauma (with or without 
PTSD) and AUDs has been reported (21, 80). From the data avail-
able, it could be deduced that later problems with AUD could be 
avoided if anxiety sensitivity in adolescents was treated first.
A systematic review of the Cochrane Database (1) showed 
the need for further research. Although there have been multiple 
RCTs for SSRIs, paroxetine and sertraline for PTSD above all, 
the evidence base for the effectiveness of medication in treat-
ing AnxDs and comorbid AUDs is currently inconclusive. The 
majority of the data for the efficacy and tolerability of medica-
tion were for SSRIs (paroxetine) in the case of social anxiety and 
AUDs (1).
Naltrexone, an opioid receptor antagonist with approved 
indications for alcohol relapse treatment in AUDs, has alleviated 
the severity of the PTSD symptoms in various open trials (86, 
88, 92, 93). However, a later 12-week naltrexone and disulfiram 
RCT in veterans did not show that naltrexone medication was 
significantly more effective than placebo in the reduction of 
PTSD symptoms (92).
It seems that patients with PTSD should be examined carefully 
because this comorbidity is a major confound in terms of etiol-
ogy, and there is not one treatment with clear evidence of efficacy 
in PTSD and AUD cases. The results for treatment medications 
remain inconclusive because of contradictory results. However, 
most studies have suggested a combination of interventions. 
Despite the contradictory results, it has been found that individu-
als with AUD and PTSD can safely be prescribed medications 
used in non co-occurring populations, and patients improve with 
treatment (101).
Comorbid AD and AUD Pharmacological 
Treatment Considerations
Atypical Antipsychotics
A systematized review in non-comorbid conditions (60) sup-
ported the evidence that only a few atypical antipsychotics are 
effective in only a minority of the off-label conditions in which 
they are currently used, confirming that atypical antipsychotics 
are not all the same. Their use should be determined on the basis 
of a balance between efficacy and side effects, their characteristics 
and the patient’s preference.
Use of Antidepressants
Selective serotonin reuptake inhibitors are the first choice drugs 
in non-comorbid anxiety and AUD treatments (1, 15, 102). 
However, their effectiveness in AnxDs and AUDs is not so clear. 
There seems to be quite a large amount of data on the effective-
ness of the SSRIs; however, there have been few rigorous studies, 
reflected in the very low quality of evidence that the results 
provide (1). High general levels of treatment discontinuation 
were observed in some of the randomized controlled trials. 
Consequently, there is little evidence of any effect of the SSRIs on 
abstinence from alcohol use, with the exception of the tricyclic 
antidepressant desipramine (1). However, at the clinical level, tri-
cyclic antidepressants are not recommended due to their adverse 
effects and interactions (45).
The effectiveness for the SSRIs for alcohol consumption reduc-
tion is not very convincing. There is some evidence that the SSRIs 
can produce favorable results in the treatment of patients with less 
severe alcohol dependence, but these drugs can worsen the alcohol 
consumption results when combined with Cognitive–Behavioral 
Therapy in severe alcohol dependence patients (45). It should be 
emphasized that, in some trials, SSRIs were found to be inferior 
to placebo in the treatment of AUDs, demonstrating a sort of 
facilitating effect with regard to relapse. This point is relevant, 
and clinicians need to know it. Of course, when the comorbid 
disorder is relevant, there is probably a place for this treatment, 
but when the role of the AUD is prevalent, some reflections must 
be undertaken.
The reduction of social anxiety symptoms reported by 
patients (as part of an alcohol detoxification protocol) treated 
with mirtazapine and noradrenergic and specific serotonergic 
antidepressants suggested that drugs that target the neurotrans-
mitter systems involved could be beneficial in the treatment of 
anxiety, as well as AUDs (45, 64). These results were later not 
confirmed in antidepressants such as venlafaxine, which act on 
both the serotonergic and noradrenergic systems.
Use of Anxiolytics
There are strong evidence and recommendations supporting 
the use of BZD for the treatment of the symptoms and signs of 
alcohol withdrawal syndrome and the prevention of seizures. 
TAble 3 | Recommendations for the use of psychopharmacological treatment in 
patients with comorbid AnxDs and AUDs.
Strength of  
recommendationa (41)
Conclusions/level of evidenceb (46)
C Low dosage of sedative antipsychotics for AnxD 
treatment in AUD patients
Level of evidence: 4
C Noradrenergic and specific serotonergic 
antidepressants: preliminary evidence was 
found: combined treatment—psychotherapy and 
mirtazapine—has an impact on the remission of AnxD 
symptoms in AUD patients
Level of evidence: 4
A Antidepressants: non-selective monoamine reuptake 
inhibitors—nefazodone has shown efficacy in anxiety 
symptom remission and in the reduction of number 
of drinks
Level of evidence: 1a
A Antidepressants: selective serotonin reuptake 
inhibitors. It was with paroxetine that the most 
scientific evidence was found for the AnxD treatment 
in AUD patients. In the same manners, various RCTs 
showed the efficacy of sertraline in PTSD treatment in 
AUD patients
Level of evidence: 1a
B Caution in the use of benzodiazepines (BZD) is 
recommended due to a greater risk of developing 
tolerance and dependence in patients with alcohol use 
and AnxDs
Level of evidence: 2a
A The use of BZD is recommended only for alcohol 
detoxification patients under clinical monitoring; in no 
case should the treatment be longer than 4 weeks
Level of evidence: 1a
A Buspirone was found effective for alcohol-dependent 
patients with comorbid anxiety
Level of evidence: 1a
A Gabapentin was found effective for anxiety and AUD 
treatment
Level of evidence: 1a
A Pregabalin was found effective in the remission of 
specific symptoms for anxiety, hostility and psychosis
Level of evidence: 1a
A Topiramate has shown the capacity to improve 
symptoms of anxiety in patients with alcohol use 
disorder
Level of evidence: 1b
A Use of opioid antagonists in patients with AnxD and 
AUD. Naltrexone was found to be effective in the 
remission of AnxD and improvement of abstinence rates
Level of evidence: Ia.
A Psychotherapeutics was found effective in the 
treatment of dual anxiety
Level of evidence: 1a
aThe OCEBM (41) Grades of Recommendation: A, consistent level 1 studies; B, 
consistent level 2 or 3 studies or extrapolations from level 1 studies; C, level 4 studies 
or extrapolations from level 2 or 3 studies.
bThe OCEBM (41) Levels of Evidence: 1a, systematic review (with homogeneity) of 
prospective cohort studies; 1b, prospective cohort study with good follow-up; 2a, 
systematic review (with homogeneity) of 2b and better studies; 4, case-series or 
superseded reference standards.
AnxD, anxiety disorder; AUD, alcohol use disorder.
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Its continuous use is, however, not recommended (1, 45, 80). The 
use of BZD revealed no predictive effects of relapse or recovery 
in AUD patients in long-term treatment (81). Buspirone was 
found to be effective in comorbid AUD and AnxD patients (77, 
81, 82). The use of BZD revealed no predictive effects of relapse or 
recovery in AUD patients in long-term treatment (1). The NMDA 
receptor antagonist-benzodiazepine has been involved in abuse 
liability (26, 102). So these medications should be used very care-
fully in the alcohol-dependent patients.
Use of Anticonvulsants
There have been promising results in the use of gabapentin and 
pregabalin in AnxD and AUD patients (87–92). However, there have 
been recent reviews of the possibility of pregabalin abuse and studies 
of cases concerning the abuse of gabapentin in patients with histories 
of substance abuse. As clinicians, we should be vigilant and remain 
alert to the appearance of signs of abuse among our patients (91).
Use of Opioid Antagonists
In AUD treatment, naltrexone injections did not provide any sig-
nificant benefit in relapse, nor did it lower the numbers of binge 
drinks. Additionally, controlled clinical trials could not prove the 
efficacy of disulfiram, except in patients with a good adherence 
to treatment (1).
There is moderate evidence of efficacy for the off-label use 
of the drugs nalmefene and topiramate in the improvement of 
some alcohol consumption outcomes, and there is also limited 
evidence concerning valproic acid (1, 15, 45).
Acamprosate and naltrexone have the best evidence support-
ing their efficacy, but head-to-head trials have not consistently 
established the superiority of either medication. Thus, other 
factors can contribute to medication choices, such as frequency 
of administration, potential adverse events, and the availability 
of treatments.
Comorbid AD and AUD Psychotherapeutic 
interventions Considerations
Psychotherapeutic interventions have shown ample evidence of their 
efficacy in dual anxiety treatment. The NICE guidelines recommend 
addiction-focused counseling and training in coping strategies for 
substance-induced AnxDs. Specific psychological, motivational, 
and cognitive behavioral techniques/therapies should be applied in 
disorders that remain after abstinence has been established (103).
The use of specific pharmacological treatment of AUDs 
comorbid with AnxDs could be modulated on the basis of craving 
typologies. Identifying a craving type may represent an important 
predicting or matching variable for anti-craving psychotropics 
that could be determined using specific rating strategies (104).
Table 3 shows a summary of proposed recommendations for 
the treatment of patients with comorbid AnxDs and AUDs, based 
on the review of the literature performed.
CONClUSiON
That AUD and AnxD can reinforce one another (mutual- 
maintenance) indicates that treatments targeting both pathologies 
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and pregabaline should be taken into account (90, 91). A 
study (86) shows that Topiramate could improve anxiety 
symptoms in alcohol-dependent patients, while some benefits 
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